Pennsylvania House Bill HB2363

Pennsylvania 2023-2024 Regular Session

• Introduced: 6/3/24
• Refer: 6/3/24
• Refer: 6/12/24
• Report Pass: 9/23/24

Caption

Further providing for title and short title of act, for definitions, for establishment of program, for restocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity, providing for annual report and for list of approved participating pharmacies and further providing for regulations.

Impact

The bill's modification of the repository program could significantly improve access to necessary medications for those who are financially disadvantaged. By enabling pharmacies to restock and dispense a larger variety of prescription drugs, HB2363 responds to public health needs while supporting a system that maximizes the utility of available medical resources. Additionally, the act includes provisions to hold pharmacies accountable through annual reporting and the establishment of eligibility criteria, which likely addresses regulatory concerns about the proper use of donated medications.

Summary

House Bill 2363, known as the Prescription Drug Repository Program Act, aims to enhance access to uneaten cancer prescription drugs for indigent patients by amending existing regulations surrounding the donation and dispensing of these medications. The act seeks to establish clearer definitions, guidelines, and responsibilities for both participating pharmacies and the State Board of Pharmacy regarding how donated drugs can be managed and dispensed. By broadening the definition from 'cancer drugs' to 'prescription drugs,' the bill also opens the door for a wider range of medications to be included, thus potentially increasing benefits for patients in vulnerable situations.

Sentiment

The sentiment surrounding HB2363 appears to be largely positive among proponents, who argue that the bill represents a crucial step toward improving health equity. Supporters, including various health advocates, see the potential for saving lives and reducing suffering among low-income cancer patients. However, concerns remain about ensuring that all drugs donated meet safety and efficacy standards, as well as how the new guidelines for pharmacies will be implemented without overwhelming them with regulatory burdens.

Contention

While the bill has garnered support for its noble objectives, it has also faced scrutiny, particularly regarding the implications for how drugs will be approved for re-dispensing. Notable points of contention include how the definitions of eligible medications will be interpreted by the State Board of Pharmacy and the need for rigorous regulations on the handling and distribution of these drugs. There is a concern that, without meticulous oversight, the program might inadvertently expose patients to risks by distributing improperly managed medications.